Articles from Osteal Therapeutics

Presentations will address 24-month treatment outcomes, systemic antibiotic exposure, and new treatment strategies for recalcitrant periprosthetic joint infection

Outcomes at 12 months demonstrate a statistically significant net treatment effect of 19% compared to the standard of care two-stage exchange arthroplasty and highlight a 71% reduction in PJI burden

The six-month efficacy endpoint of overall success showed a statistically significant improvement over standard of care, two-stage exchange arthroplasty

Financing led by Zimmer Biomet with participation from existing investors Johnson & Johnson Innovation – JJDC, Inc., Gideon Strategic Partners, and HM Capital.

Breakthrough Therapy Designation for VT-X7 builds upon previous Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track Designations

President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients

Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM Capital, Prism Ventures and Medvest Capital.

The second Phase 2 clinical trial known as APEX-2 will augment the VT-X7 safety and efficacy data collected in the APEX trial.

Four new executives from the life science industry each bring over twenty years of experience in the development, approval and commercialization of high impact biopharmaceutical products.

Six-month outcomes are expected in second quarter of 2023